Jazz Pharmaceuticals (JAZZ) PT Raised to $201 at Piper Jaffray
February 28, 2018 6:11 AM
Piper Jaffray raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $201.00 (from $194.00) while maintaining a Overweight rating.Analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
